CRP and spondylitis: Similar outcomes were shown for the secondary endpoints, which included a decrease in the score of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Quality of Life (ASQoL), Short-Form (SF)-36 health survey, and levels of C-reactive protein (CRP) [40]. Many complications have been documented in the study of Baeten et al. [40] and are relevant to previous studies regarding safety concerns about using secukinumab [38,39].